T cell receptor specific for influenza A H3N2 hemagglutinin-derived peptide (H3N2 HA-specific TCR)

T cell receptors (TCRs) specific for influenza A H3N2 hemagglutinin-derived peptides are specialized heterodimeric proteins on T lymphocytes that mediate the recognition of influenza virus antigens (PubMed: 28258200). These receptors specifically bind to peptide fragments of the H3N2 hemagglutinin (HA) protein, such as the immunodominant HA306-318 epitope, when presented by Major Histocompatibility Complex (MHC) molecules (IEDB: 50514). This interaction is a cornerstone of the adaptive immune response, facilitating the activation of CD4+ helper T cells and CD8+ cytotoxic T cells to control viral replication and clear the infection (PubMed: 31160518). In the context of H3N2, which frequently undergoes antigenic drift, these TCRs are vital for providing cross-reactive immunity against evolving viral strains (PubMed: 25231595). Therapeutic strategies targeting or utilizing these TCRs include the design of universal influenza vaccines and the development of adoptive T-cell therapies to enhance viral clearance in immunocompromised patients (PubMed: 30635454). However, challenges such as TCR cross-reactivity with self-peptides and the potential for cytokine release syndrome remain significant safety considerations in clinical applications (PubMed: 29434354). The study of these receptors also aids in monitoring vaccine efficacy through the analysis of TCR repertoire diversity and antigen-specific T cell frequencies.

Other names

Influenza A H3N2 hemagglutinin-specific T-cell receptorH3N2 HA-specific TCRHemagglutinin-specific T-cell receptorHA-specific TCR

Recognition of influenza A H3N2 hemagglutinin peptides presented by Major Histocompatibility Complex (MHC) molecules, leading to T cell activation, proliferation, and effector functions such as cytokine release or direct lysis of infected cells (PubMed: 28258200).